Lifecore Biomedical, Inc.

What they do

Lifecore provides clinical and commercial development, cGMP manufacturing and aseptic filling of complex, highly viscous sterile injectables in syringes, vials and cartridges. It also makes pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA) via a proprietary fermentation process for bulk sale and for customers' ophthalmic and orthopedic injectable products. Operations run across three cGMP facilities with semi-automated RABS and fully automated isolator filling lines, plus development services from analytical method validation through process validation and clinical materials.

Revenue drivers

• CDMO — Aseptic formulation and filling of syringes, vials and cartridges plus product development services; $90.1 million of fiscal 2025 revenue, down 7% from $96.6 million in fiscal 2024.
• HA manufacturing — Production and sale of bulk pharmaceutical-grade, non-animal-sourced HA; $38.8 million of fiscal 2025 revenue, up 23% from $31.6 million, driven by the largest customer's supply chain initiatives.
• Development services — Feeds the commercial pipeline but fluctuates with project lifecycles; fiscal 2025 development revenue fell $6.2 million after a discrete prior-year project completed.
• Customer pricing and take-or-pay — Fiscal 2025 CDMO revenue included $5.4 million of value-focused pricing initiatives and $1.8 million from a contractual take-or-pay arrangement.

Recent performance

Fiscal 2025 revenue was $128.9 million, essentially flat versus $128.3 million in fiscal 2024, with CDMO declines offset by HA growth. Gross profit fell 4% to $40.3 million as gross margin slipped to 31.3% from 32.6%. Fiscal 2025 net loss was $38.7 million and operating cash flow was negative $206 thousand, versus net income of $12.0 million and positive operating cash flow of $257 thousand in fiscal 2024. At June 30, 2026, the latest balance sheet shows total assets of $229.5 million, total liabilities of $213.4 million, shareholders' equity of negative $34.1 million, cash of $17.2 million and long-term debt of $155.1 million. Quarterly revenue was $23.2 million in the March 2026 quarter and $34.2 million in the June 2026 quarter.

Strategy

Management has pursued a standalone CDMO strategy since divesting the legacy food businesses in May 2023. In September 2024 it doubled revenue-generating capacity to support up to roughly $300 million in annual revenue by installing a fully automated high-speed 5-head aseptic isolator filler. Financial actions included a $24.3 million October 2024 private placement, a three-year extension of the BMO asset-based revolving credit facility, a $17 million January 2025 sale of excess equipment, and cost reductions. The company also appointed a new CEO in May 2024 and new CFO in September 2024, settled a cooperation agreement with 22NW, LP, regained Nasdaq compliance in August 2024, and increased sales and marketing investment with new business development hires. Management describes a three-pronged growth plan: maximize existing customer business, advance late-stage development programs to commercialization, and win new business.

Risks

• Material weaknesses in internal control — The company has identified material weaknesses in internal control over financial reporting that affected the reliability of its financial statements and may have further adverse consequences.
• High leverage and debt obligations — The company carries long-term debt of $155.1 million and states it is highly leveraged and subject to significant interest, fair value and credit agreement obligations, some expected to grow.
• History of losses and cash needs — Lifecore reported a $38.7 million net loss in fiscal 2025 with negative operating cash flow, and its forward-looking disclosures flag the timing and availability of, and need for, additional financing.
• Customer concentration and lifecycle timing — Fiscal 2025 results were heavily affected by one large HA customer's supply-chain initiatives as well as a development project completion, reduced customer volumes and a customer termination in CDMO.

Outlook

Management targets a 12+% revenue CAGR and Adjusted EBITDA margins above 25%, and describes a significant inflection point in existing commercial customer demand beginning in 2027. It cites a high-growth market expected to double by 2030, capacity and capital investments that enable scale, and potential upside to contractual minimums. The company also notes it may use cash resources or need to raise additional financing in 2026 or the near term. Explicit financial guidance for 2026 and a longer-term outlook are referenced in its investor materials.